

### SWOG ASCO ABSTRACTS 2017

Study	Abstract Title/Citation/Abstract Link	Authors	Abstract Number	Session Time & Place
S0221	SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy. J Clin Oncol 35, 2017 (suppl; abstr 521). <a href="http://abstracts.asco.org/199/AbstView_199_184069.html">http://abstracts.asco.org/199/AbstView_199_184069.html</a>	G. Thomas Budd, William E. Barlow, Halle C. F. Moore, Timothy J. Hobday, James A. Stewart, Claudine Isaacs, Muhammad Salim, Jonathan K. Cho, Kristine Rinn, Kathy S. Albain, Helen K. Chew, Gary Von Burton, Timothy David Moore, Gordan Srkalovic, Bradley Alexander McGregor, Lawrence E. Flaherty, Robert B. Livingston, Danika L Lew, Julie Gralow, Gabriel N. Hortobagyi	521	Session: Breast Cancer—Local/Regional/Adjuvant Type: Poster Session Board #121 Time: Sunday June 4, 8:00 AM to 11:30 AM Location: Hall A
S0715	Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715). J Clin Oncol 35, 2017 (suppl; abstr 10093). <a href="http://abstracts.asco.org/199/AbstView_199_184547.html">http://abstracts.asco.org/199/AbstView_199_184547.html</a>	Dawn L. Hershman, Joseph M. Unger, Katherine D. Crew, Cyrus Ebnesajjad, Heather Greenlee, Louis Fehrenbacher, Carol Moinpour, Lori M. Minasian, Danika L Lew, Siu-Fun Wong, James Lloyd Wade, Michael Fisch, Kathy S. Albain, Norah Lynn Henry	10093	Session: Patient and Survivor Care Type: Poster Session Board #82 Time: Saturday June 3, 1:15 PM to 4:45 PM Location: Hall A
S0800	Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial. J Clin Oncol 35, 2017 (suppl; abstr 519). <a href="http://abstracts.asco.org/199/AbstView_199_189568.html">http://abstracts.asco.org/199/AbstView_199_189568.html</a>	Vasiliki Pelekanou, William E. Barlow, Marie-Kristin von Wahlde, Brad Wasserman, Ying-Chun Lo, Daniel F. Hayes, Gabriel N. Hortobagyi, Julie Gralow, Debu Tripathy, Robert B. Livingston, Peggy Porter, Zeina A. Nahleh, David L. Rimm, Lajos Pusztai	519	Session: Breast Cancer—Local/Regional/Adjuvant Type: Poster Session Board #199 Time: Sunday June 4, 8:00 AM to 11:30 AM Location: Hall A Session: Breast Cancer—Local/Regional/Adjuvant Type: Poster Discussion Session Time: Sunday June 4, 11:30 AM to 12:45 PM Location: Hall D2

S0931	Everolimus (EVE) exposure as a predictor of toxicity (Tox) in renal cell cancer (RCC) patients (Pts) in the adjuvant setting: Results of a pharmacokinetic analysis for SWOG S0931 (EVEREST), a phase III study (NCT01120249). J Clin Oncol 35, 2017 (suppl; abstr 4566). <a href="http://abstracts.asco.org/199/AbstView_199_190176.html">http://abstracts.asco.org/199/AbstView_199_190176.html</a>	Timothy W. Synold, Melissa Plets, Catherine M. Tangen, Elisabeth I. Heath, Ganesh S. Palapattu, Philip C. Mack, Mark N. Stein, Maxwell V. Meng, Primo Lara, Nicholas J. Vogelzang, Ian Murchie Thompson, Christopher W. Ryan	4566	Session: Genitourinary (Nonprostate) Cancer Type: Poster Session (Board #244 Time: Sunday June 4, 8:00 AM to 11:30 AM Location: Hall A
S1201	A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 for advanced/ metastatic esophageal, gastric, or gastroesophageal junction cancer: SWOG S1201. J Clin Oncol 35, 2017 (suppl; abstr 4009). <a href="http://abstracts.asco.org/199/AbstView_199_186970.html">http://abstracts.asco.org/199/AbstView_199_186970.html</a>	Syma Iqbal, Shannon McDonough, Heinz-Josef Lenz, David H. Ilson, Barbara Burtness, Chaitali Singh Nangia, Afsaneh Barzi, Charles Schneider, Jijun Liu, Efrat Dotan, Katherine A Guthrie, Howard S. Hochster	4009	Session: GI (Noncolorectal) Ca Type: Poster Session Board #1 Time: Saturday June 3, 8:00 AM to 11:30 AM Location: Hall A  Session: GI (Noncolorectal) Ca Type: Poster Discussion Session Time: Saturday June 3, 4:45 PM to 6:00 PM Location: Hall D2
S1221	SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173). J Clin Oncol 35, 2017 (suppl; abstr 2578). <a href="http://abstracts.asco.org/199/AbstView_199_184767.html">http://abstracts.asco.org/199/AbstView_199_184767.html</a>	Alain Patrick Algazi, James Moon Chmielowski, Roger Lo, Kari Lynn Kendra, Christopher D. Lao, Gonzalez, Kevin Kim, John E. Godwin, Brendan D. Curti, Megan Othus, Antoni Ribas	2578	Session: Developmental Therapeutics Pharmacology and Experimental Type: Poster Session Board #70 Time: Monday June 5, 8:00 AM to Location: Hall A
S1310	SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer. J Clin Oncol 35, 2017 (suppl; abstr 4016). <a href="http://abstracts.asco.org/199/AbstView_199_187183.html">http://abstracts.asco.org/199/AbstView_199_187183.html</a>	Richard D. Kim, Shannon L McDonough, Anthony B. El-Khoueiry, Tanius S. Bekaii-Saab, Stacey Stein, Vaibhav Sahai, George P. Keogh, Edward David Baron, Abby B. Siegel, Afsaneh Barzi, Katherine Guthrie, Howard S. Hochster	4016	Session: GI (Noncolorectal) Ca Type: Poster Session Board #8 Time: Saturday June 3, 8:00 AM to 11:30 AM Location: Hall A Session: GI (Noncolorectal) Ca Type: Poster Discussion Session Time: Saturday June 3, 4:45 PM to Location: Hall D2

S1400B	A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B. J Clin Oncol 35, 2017 (suppl; abstr 9054). <a href="http://abstracts.asco.org/199/AbstView_199_188460.html">http://abstracts.asco.org/199/AbstView_199_188460.html</a>	James Lloyd Wade, Corey J. Langer, Mary Redman, Charu Aggarwal, Jeffrey D Bradley, Jeffrey Crawford, Jieling Miao, Katie Griffin, Roy S. Herbst, Karen Kelly, David R. Gandara, Vassiliki Papadimitrakopoulou	9054	Session: Lung Cancer—Non-Small Cell Metastatic Type: Poster Session Board #380 Time: Saturday June 3, 8:00 AM to 11:30 AM Location: Hall A
S1400C	A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C. J Clin Oncol 35, 2017 (suppl; abstr 9056). <a href="http://abstracts.asco.org/199/AbstView_199_186002.html">http://abstracts.asco.org/199/AbstView_199_186002.html</a>	Martin J. Edelman, Mary Weber Redman, Kathy S. Albain, Eric C. McGary, Norman Rafique, Daniel P. Petro, Saiama Naheed Waqar, Jieling Miao, Katie Griffin, Vassiliki Papadimitrakopoulou, Karen Kelly, David R. Gandara, Roy S. Herbst	9056	Session: Lung Cancer—Non-Small Cell Metastatic Type: Poster Session Board #382 Time: Saturday June 3, 8:00 AM to 11:30 AM Location: Hall A
S1400D	Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D. J Clin Oncol 35, 2017 (suppl; abstr 9055). <a href="http://abstracts.asco.org/199/AbstView_199_191100.html">http://abstracts.asco.org/199/AbstView_199_191100.html</a>	Charu Aggarwal, Mary Weber Redman, Primo Lara, Hossein Borghaei, Philip C. Hoffman, Jeffrey D. Bradley, Katie Griffin, Jieling Miao, Philip C. Mack, Vassiliki Papadimitrakopoulou, Roy S. Herbst, Karen Kelly, David R. Gandara	9055	Session: Lung Cancer—Non-Small Cell Metastatic Type: Poster Session Board #381 Time: Saturday June 3, 8:00 AM to 11:30 AM Location: Hall A
S1406	Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol 35, 2017 (suppl; abstr 3505). <a href="http://abstracts.asco.org/199/AbstView_199_194502.html">http://abstracts.asco.org/199/AbstView_199_194502.html</a>	Scott Kopetz, Shannon L McDonough, Heinz-Josef Lenz, Anthony Martin Magliocco, Chloe Evelyn Atreya, Luis A. Diaz, Carmen Joseph Allegra, Kanwal Pratap Singh Raghav, Van Karllye Morris, Stephen E. Wang, Christopher Hanyoung Lieu, Katherine A Guthrie, Howard S. Hochster	3505	Session: GI (Colorectal) Ca Type: Oral Abstract Session Time: Monday June 5, 3:00 PM to 6:00 PM Location: Hall D2
S1500	A randomized, phase II efficacy assessment of multiple MET kinase inhibitors in metastatic papillary renal carcinoma (PRCC): SWOG S1500. J Clin Oncol 35, 2017 (suppl; abstr TPS4599). <a href="http://abstracts.asco.org/199/AbstView_199_187390.html">http://abstracts.asco.org/199/AbstView_199_187390.html</a>	Sumanta K. Pal, Catherine M. Tangen, Ian Murchie Thompson, Brian M. Shuch, Naomi B. Haas, Daniel J. George, Mark N. Stein, John Joseph Wright, Melissa Plets, Primo Lara	TPS4599	Session: Genitourinary (Non-prostate) Cancer Type: Poster Session Board #272b Time: Sunday June 4, 8:00 AM to 11:30 AM Location: Hall A

S1513	Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513. J Clin Oncol 35, 2017 (suppl; abstr TPS4147). <a href="http://abstracts.asco.org/199/AbstView_199_186366.html">http://abstracts.asco.org/199/AbstView_199_186366.html</a>	E. Gabriela Chiorean, Shannon McDonough, Philip Agop Philip, Elizabeth M. Swisher, Michael J. Pishvaian, Katherine Guthrie, Andrew M. Lowy, Howard S. Hochster	TPS4147	Session: GI (Noncolorectal) Ca Type: Poster Session Board 131a Time: Saturday June 3, 8:00 AM to 11:30 AM Location: Hall A
S1605	S1605: Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer. J Clin Oncol 35, 2017 (suppl; abstr TPS4591). <a href="http://abstracts.asco.org/199/AbstView_199_184714.html">http://abstracts.asco.org/199/AbstView_199_184714.html</a>	Parminder Singh, Tangen Catherine, Seth P. Lerner, David McConkey, Melissa Plets, M. Scott Lucia, Michael Woods, Trinity Bivalacqua, Wassim Kassouf, Richard Carlton Bangs, Ian Murchie Thompson, Peter C. Black	TPS4591	Session: Genitourinary (Nonprostate) Cancer Type: Poster Session Board #268b Time: Sunday June 4, 8:00 AM to 11:30 AM Location: Hall A
S9313	Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313). J Clin Oncol 35, 2017 (suppl; abstr 529). <a href="http://abstracts.asco.org/199/AbstView_199_193082.html">http://abstracts.asco.org/199/AbstView_199_193082.html</a>	Priyanka Sharma, William E. Barlow, Andrew K. Godwin, Laura A Knight, Steven M. Walker, Richard D. Kennedy, Sunil S. Badve, Yesim Gokmen-Polar, Harsh B Pathak, Kamilla Isakova, Hannah M. Linden, Debu Tripathy, Gabriel N. Hortobagyi, Daniel F. Hayes	529	Session: Breast Cancer—Local/Regional/Adjuvant Type: Poster Session Board #129 Time: Sunday June 4, 8:00 AM to 11:30 AM Location: Hall A
S9921	Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921. J Clin Oncol 35, 2017 (suppl; abstr 5019). <a href="http://abstracts.asco.org/199/AbstView_199_183222.html">http://abstracts.asco.org/199/AbstView_199_183222.html</a>	Maha Hussain, Catherine M. Tangen, Ian Murchie Thompson, Gregory P. Swanson, David Peter Wood, Wael Sakr, Nancy Ann Dawson, Naomi B. Haas, Thomas W. Flaig, Tanya B. Dorff, Daniel W. Lin, E. David Crawford, David I. Quinn, Nicholas J. Vogelzang, L. Michael Glode	5019	Session: Genitourinary (Prostate) Cancer Type: Poster Session Board # 93 Time: Monday June 5, 1:15 PM to 4:45 PM Location: Hall A  Session: Genitourinary (Prostate) Cancer Type: Poster Discussion Session Time: Monday June 5, 4:45 PM to 6:00 PM Location: Arie Crown Theater

Multiple	Patterns of osteoporosis (OP) in survivors of colorectal cancer (CRC) enrolled on SWOG trials. J Clin Oncol 35, 2017 (suppl; abstr 10056). <a href="http://abstracts.asco.org/199/AbstView_199_184332.html">http://abstracts.asco.org/199/AbstView_199_184332.html</a>	Afsaneh Barzi, Dawn L. Hershman, Cathee Till, Heinz-Josef Lenz, Howard S. Hochster, Joseph M. Unger	10056	Session: Patient and Survivor Care Type: Poster Session Board #45 Time: Saturday June 3, 1:15 PM to 4:45 PM Location: Hall A
Multiple	Impact of value of research analyses on SWOG's clinical trial capsule scoring. J Clin Oncol 35, 2017 (suppl; abstr e18311). <a href="http://abstracts.asco.org/199/AbstView_199_191486.html">http://abstracts.asco.org/199/AbstView_199_191486.html</a>	Josh John Carlson, David Kim, Gregory F. Guzauskas, Caroline Savage Bennette, Dawn L. Hershman, Laurence H. Baker, Nathaniel Hendrix, Anirban Basu, David Leroy Veenstra, Scott Ramsey	e18311	n/a
Multiple	The scientific impact and value of large, NCI-sponsored randomized phase III cancer prevention trials. J Clin Oncol 35, 2017 (suppl; abstr 1541). <a href="http://abstracts.asco.org/199/AbstView_199_181935.html">http://abstracts.asco.org/199/AbstView_199_181935.html</a>	Joseph M. Unger, William E. Barlow, Catherine M. Tangen, Scott David Ramsey, Ian Murchie Thompson, Eric A. Klein, Michael Leo LeBlanc, Charles David Blanke, Phyllis J. Goodman, Lori M. Minasian, Dawn L. Hershman	1541	Session: Cancer Prevention, Genetics, and Epidemiology Type: Poster Session Board #199 Time: Monday June 5, 1:15 PM to 4:45 PM Location: Hall A
Multiple	The impact of positive SWOG treatment trials on population survival. J Clin Oncol 35, 2017 (suppl; abstr 6513). <a href="http://abstracts.asco.org/199/AbstView_199_182040.html">http://abstracts.asco.org/199/AbstView_199_182040.html</a>	Joseph M. Unger, Michael Leo LeBlanc, Charles David Blanke	6513	Session: Health Services Research, Clinical Informatics, and Quality of Care Type: Poster Session Board #335 Time: Monday June 5, 1:15 PM to 4:45 PM Location: Hall A  Session: Health Services Research, Clinical Informatics, and Quality of Care Type: Poster Discussion Session Time: Monday June 5, 4:45 PM to 6:00 PM Location: S504

Multiple	National coverage analyses for NCI clinical trials: A pilot project to reduce participation barriers. J Clin Oncol 35, 2017 (suppl; abstr 6542). <a href="http://abstracts.asco.org/199/AbstView_199_188423.html">http://abstracts.asco.org/199/AbstView_199_188423.html</a>	Andrea Denicoff, Grace Mishkin, Marjorie J. Good, Lucille Patrichuk, Lawrence Ragard, Kathleen R Hurtado, Kelly Willenberg, Connie M. Szczepanek, Casey Dawson, Morgen Alexander-Young, Debra L Strandberg, Julie Kardell, Sara McCartney, Mary Beth Sullivan, Michael Kelly, Michael Montello, Wortia J. McCaskill-Stevens, Jeffrey S. Abrams, Margaret M. Mooney	6542	Session: Health Services Research, Clinical Informatics, and Quality of Care Type: Poster Session Board #364 Time: Monday June 5, 1:15 PM to 4:45 PM Location: Hall A

#### ASCO 2016 Abstracts: SWOG contributions on trials led or co-led by other cooperative groups and organizations

Study	Abstract Title	Authors	Abstract Number	Session Time & Place
C80702/ Other; co-led w/ SWOG	Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. J Clin Oncol 35, 2017 (suppl; abstr LBA1)	Qian Shi, Alberto F. Sobrero, Anthony Frank Shields, Takayuki Yoshino, James Paul, Julien Taieb, Ioannis Sougklakos, Rachel Kerr, Roberto Labianca, Jeffrey A. Meyerhardt, Franck Bonnetain, Toshiaki Watanabe, Ioannis Boukovinas, Lindsay A. Renfro, Axel Grothey, Donna Niedzwiecki, Valter Torri, Thierry Andre, Daniel J. Sargent, Timothy Iveson	LBA1	Session: Plenary Session Including the Science of Oncology Award and Lecture Type: Plenary Session Time: Sunday June 4, 1:00 PM to 4:00 PM Location: Hall B1
C10404	A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance). J Clin Oncol 35, 2017 (suppl; abstr 7503). <a href="http://abstracts.asco.org/199/AbstView_199_192498.html">http://abstracts.asco.org/199/AbstView_199_192498.html</a>	Amy S. Ruppert, John C. Byrd, Nyla A. Heerema, Mitchell Reed Smith, John E. Godwin, Stephen Couban, Todd A. Fehniger, Michael Thirman, Alese E. Halvorson, Martin S. Tallman, Frederick R. Appelbaum, Richard M. Stone, Sue Robinson, Julie E. Chang, Sumithra J. Mandrekar, Richard A. Larson	7503	Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Type: Oral Abstract Session Time: Saturday June 3, 3:00 PM to 6:00 PM Location: S100bc

CALGB/ SWOG 80405	Somatic DNA mutations, MSI status, mutational load (ML): Association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance). J Clin Oncol 35, 2017 (suppl; abstr 3504). <a href="http://abstracts.asco.org/199/AbstView_199_192191.html">http://abstracts.asco.org/199/AbstView_199_192191.html</a>	Federico Innocenti, Fang-Shu Ou, Tyler Zemla, Donna Niedzwiecki, Xueping Qu, Rachel Tam, Shilpi Mahajan, Richard M. Goldberg, Robert J. Mayer, Monica M. Bertagnolli, Hanna Kelly Sanoff, Howard S. Hochster, Charles David Blanke, Alan P. Venook, Heinz-Josef Lenz, Omar Kabbarah	3504	Session: Gastrointestinal (Colorectal) Cancer Type: Oral Abstract Session Time: Monday June 5, 3:00 PM to 6:00 PM Location: Hall D2
CALGB/ SWOG 80405	Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 35, 2017 (suppl; abstr 3511). <a href="http://abstracts.asco.org/199/AbstView_199_188347.html">http://abstracts.asco.org/199/AbstView_199_188347.html</a>	Heinz-Josef Lenz, Fang-Shu Ou, Alan P. Venook, Howard S. Hochster, Donna Niedzwiecki, Richard M. Goldberg, Robert J. Mayer, Monica M. Bertagnolli, Charles David Blanke, Tyler Zemla, Xueping Qu, Federico Innocenti, Omar Kabbarah	3511	Session: Making Sense of Consensus Molecular Subtypes Type: Clinical Science Symposium Time: Tuesday June 6, 9:45 to 11:15 AM Location: E354b
CALGB/ SWOG 80405	Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance). J Clin Oncol 35, 2017 (suppl; abstr 3503). <a href="http://abstracts.asco.org/199/AbstView_199_183226.html">http://abstracts.asco.org/199/AbstView_199_183226.html</a>	Alan P. Venook, Fang-Shu Ou, Heinz-Josef Lenz, Omar Kabbarah, Xueping Qu, Donna Niedzwiecki, Tyler Zemla, Richard M. Goldberg, Howard S. Hochster, Bert H. O'Neil, Hanna Kelly Sanoff, Robert J. Mayer, Monica M. Bertagnolli, Charles David Blanke, Federico Innocenti	3503	Session: Gastrointestinal (Colorectal) Cancer Type: Oral Abstract Session Time: Monday June 5, 3:00 to 6:00 PM Location: Hall D2
C89803	Nut consumption and survival in stage III colon cancer patients: Results from CALGB 89803 (Alliance). J Clin Oncol 35, 2017 (suppl; abstr 3517). <a href="http://abstracts.asco.org/199/AbstView_199_189653.html">http://abstracts.asco.org/199/AbstView_199_189653.html</a>	Temidayo Fadelu, Donna Niedzwiecki, Sui Zhang, Xing Ye, Leonard Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Bowen Benson, Daniel M. Atienza, Michael J. Messino, Hedy L. Kindler, Alan P. Venook, Shuji Ogino, Kimmie Ng, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Ying Bao, Charles S. Fuchs	3517	Session: GI (Colorectal) Ca Type: Poster Session Board #140 Time: Saturday June 3, 8:00 to 11:30 AM Location: Hall A Session: GI (Colorectal) Ca Type: Poster Discussion Session Time: Saturday June 3, 1:15 to 2:30 PM Location: Arie Crown Theater

C89803	American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance). J Clin Oncol 35, 2017 (suppl; abstr 10006).	Erin Van Blarigan, Charles S. Fuchs, Donna Niedzwiecki, Xing Ye, Sui Zhang, Mingyang Song, Leonard Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whitton, Alexander Hantel, Al Bowen Benson, Daniel M. Atienza, Michael J. Messino, Hedy L. Kindler, Alan P. Venook, Shuji Ogino, Walter C. Willett, Edward L. Giovannucci, Jeffrey A. Meyerhardt	10006	Session: Patient and Survivor Care Type: Oral Abstract Session Time: Friday June 2, 3:00 PM to 6:00 PM Location: S102
E1609	A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms. J Clin Oncol 35, 2017 (suppl; abstr 9500). <a href="http://abstracts.asco.org/199/AbstView_199_189552.html">http://abstracts.asco.org/199/AbstView_199_189552.html</a>	Ahmad A. Tarhini, Sandra J. Lee, F. Stephen Hodi, Uma N. M. Rao, Gary I Cohen, Omid Hamid, Laura Fulper Hutchins, Jeffrey Alan Sosman, Harriet M. Kluger, Vernon K. Sondak, Henry B. Koon, Donald P. Lawrence, Kari Lynn Kendra, David R. Minor, Carrie B. Lee, Mark R Albertini, Lawrence E. Flaherty, Teresa M. Petrella, John M. Kirkwood	9500	Session: Melanoma/Skin Cancers Type: Oral Abstract Session Time: Sunday June 4, 8:00 to 11:00 AM Location: Arie Crown Theater
EA8143	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC). J Clin Oncol 35, 2017 (suppl; abstr TPS4596). <a href="http://abstracts.asco.org/199/AbstView_199_183726.html">http://abstracts.asco.org/199/AbstView_199_183726.html</a>	Lauren Christine Harshman, Maneka Puligandla, Naomi B. Haas, Mohamad Allaf, Charles G. Drake, David F. McDermott, Sabina Signoretti, David Cella, Rajan T Gupta, Rupal Satish Bhatt, Eliezer Mendel Van Allen, Toni K. Choueiri, Primo Lara, Anil Kapoor, Daniel Yick Chin Heng, Brian M. Shuch, Michael A.S. Jewett, Daniel J. George, M Dror Michaelson, Michael Anthony Carducci	TPS4596	Session: Genitourinary (Nonprostate) Cancer Type: Poster Session Board 271a Time: Sunday June 4, 8:00 to 11:30 AM Location: Hall A
N0147	Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance). J Clin Oncol 35, 2017 (suppl; abstr 3604). <a href="http://abstracts.asco.org/199/AbstView_199_193045.html">http://abstracts.asco.org/199/AbstView_199_193045.html</a>	Polly A. Newcomb, Wei Sun, Xinwei Hua, Barbara L. Banbury, Amanda I. Phipps, Jonathan Kocarnik, Tabitha A. Harrison, Qian Shi, Frank A. Sinicrope, Stephen N. Thibodeau, Emily Chan, Sharlene Gill, Richard M. Goldberg, Morton S. Kahlenberg, Suresh Nair, Anthony Frank Shields, Balkrishna N. Jahagirdar, Ulrike Peters, Steven R. Alberts, Andrew T. Chan	3604	Session: GI (Colorectal) Cancer Type: Poster Session Board #227 Time: Saturday June 3, 8:00 to 11:30 AM Location: Hall A



N0147	Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance). J Clin Oncol 35, 2017 (suppl; abstr 3579).	Frank A. Sinicrope, Qian Shi, Fabienne Hermitte, Erica N Heying, Al Bowen Benson, Sharlene Gill, Richard M. Goldberg, Morton S. Kahlenberg, Suresh Nair, Anthony Frank Shields, Daniel J. Sargent, Jerome Galon, Steven R. Alberts	3579	Session: GI (Colorectal) Cancer Type: Poster Session Board #202 Time: Saturday June 3, 8:00 to 11:30 AM Location: Hall A
N0147	Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance). J Clin Oncol 35, 2017 (suppl; abstr 3516). <a href="http://abstracts.asco.org/199/AbstView_199_193534.html">http://abstracts.asco.org/199/AbstView_199_193534.html</a>	Frank A. Sinicrope, Qian Shi, Thomas C. Smyrk, Richard M. Goldberg, Erica N Heying, Steven J. Cohen, Sharlene Gill, Morton S. Kahlenberg, Suresh Nair, Anthony Frank Shields, Daniel J. Sargent, Balkrishna N. Jahagirdar, Michael N. Pollak, Steven R. Alberts	3516	Session: GI (Colorectal) Cancer Type: Poster Session Board #139 Time: Saturday June 3, 8:00 to 11:30 AM Location: Hall A  Session: GI (Colorectal) Cancer Type: Poster Discussion Session Time: Saturday June 3, 1:15 to 2:30 PM Location: Arie Crown Theater